SUMMARY OF ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Schedule of cumulative effect adjustment and the impact on current period financial statements of adopting Topic 606

	Three months ended March 31, 2019 (unaudited)
	prior U.S. GAAP			Topic 606 impact			as reported
Statement of Operations
Revenues
Product	$	554,357		$	(383,096	)	$	171,261
Service		663,816			(56,609	)		607,207
Total revenues		1,218,173			(439,705	)		778,468
Cost of revenues		136,474			(3,333	)		133,141
Loss from operations		(2,196,265	)		(436,372	)		(2,632,637	)

	Six months ended March 31, 2019 (unaudited)
	prior U.S. GAAP			Topic 606 impact			as reported
Statement of Operations
Revenues
Product	$	1,259,329		$	(766,192	)	$	493,137
Service		1,233,891			(64,237	)		1,169,654
Total revenues		2,493,220			(830,429	)		1,662,791
Cost of revenues		293,293			(6,667	)		286,626
Loss from operations		(5,005,032	)		(823,763	)		(5,828,795	)
Assets
Prepaids and other current assets	$	597,736		$	(6,667	)	$	591,069
Liabilities and stockholder's equity
Deferred Revenue	$	875,232		$	330,237		$	1,205,469
Accumulated Deficit		(253,463,700	)		(330,237	)		(253,793,937	)

Schedule of operations and timing of revenue recognition

	Three Month Period Ended:
	March 31, 2019		March 31, 2018
Research and development services (over-time)	$	559,568	$	476,623
Product and authentication services (point-in-time):
Supply chain		20,234		136,965
Asset marking		158,078		239,646
Large scale DNA production		40,588		190,712
Total	$	778,468	$	1,043,946

	Six Month Period Ended:
	March 31, 2019		March 31, 2018
Research and development services (over-time)	$	1,057,917	$	698,488
Product and authentication services (point-in-time):
Supply chain		244,983		206,817
Asset marking		319,303		487,668
Large scale DNA production		40,588		298,650
Total	$	1,662,791	$	1,691,623

Schedule of opening and closing contract balances

	Balance sheet classification	October 1, 2018		March 31, 2019		$ change
Contract liabilities	Deferred revenue	$	1,356,502	$	1,205,469	$	(151,033	)

Schedule of anti-dilutive securities not included computation of net loss per share

	2019		2018
Warrants		16,885,427		12,271,686
Stock options		6,458,194		5,320,308
		23,343,621		17,591,994